Newsbenzinga
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
· Published
Article summary
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
An excerpt from the original article.
Comments —
Loading comments…